Risk factors for mortality before age 18 years in cystic fibrosis

Pediatric Pulmonology

Volumn 52, Issue 7, 2017, Pages 909-915

  McColley, Susanna A ^a   Schechter, Michael S ^b   Morgan, Wayne J ^c   Pasta, David J ^d   Craib, Marcia L ^d   Konstan, Michael W ^e  

^a NORTHWESTERN UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d ICON CLINICAL RESEARCH   (United States)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cystic fibrosis; health disparities; mortality

Indexed keywords

ADOLESCENT; ARTICLE; BACTERIUM CULTURE; CHILD; CHILD DEATH; CRACKLE; CYSTIC FIBROSIS; ETHNICITY; FEMALE; FORCED EXPIRATORY VOLUME; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MORTALITY RATE; NUTRITIONAL PARAMETERS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RISK FACTOR; SEX DIFFERENCE; ABNORMAL RESPIRATORY SOUND; ANCESTRY GROUP; BODY WEIGHT; ETHNIC GROUP; GENETICS; MORTALITY; PATHOPHYSIOLOGY; PRESCHOOL CHILD; PSEUDOMONAS INFECTION; REGISTER;

CFTR PROTEIN, HUMAN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR;

ADOLESCENT; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; CONTINENTAL POPULATION GROUPS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; ETHNIC GROUPS; FEMALE; GENOTYPE; HUMANS; MALE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; REGISTRIES; RESPIRATORY SOUNDS; RISK FACTORS;

EID: 85018861282     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.23715     Document Type: Article

References (25)

1. Knapp EA, Fink AK, Goss CH, et al. The cystic fibrosis foundation patient registry: design and methods of a national observational disease registry. Ann Am Thorac Soc. 2016; 13:1173–1179.
2. Yen EH, Quinton H, Borowitz D. Better nutritional status in early childhood is associated with improved clinical outcomes and survival in patients with cystic fibrosis. J Pediatr. 2013; 162:530–535 e531.
3. Konstan MW, Butler SM, Wohl ME, et al. Investigators, Coordinators of the Epidemiologic Study of Cystic F. Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis. J Pediatr. 2003; 142:624–630.
4. Kerby GS, Rosenfeld M, Ren CL, et al. Lung function distinguishes preschool children with CF from healthy controls in a multi-center setting. Pediatr Pulmonol. 2012; 47:597–605.
5. Subbarao P, Milla C, Aurora P, et al. Multiple-Breath washout as a lung function test in cystic fibrosis. a cystic fibrosis foundation workshop report. Ann Am Thorac Soc. 2015; 12:932–939.
6. Morgan WJ, Butler SM, Johnson CA, et al. Epidemiologic study of cystic fibrosis: design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada. Pediatr Pulmonol. 1999; 28:231–241.
7. McColley SA, Ren CL, Schechter MS, et al. Epidemiologic Study of Cystic F. Risk factors for onset of persistent respiratory symptoms in children with cystic fibrosis. Pediatr Pulmonol. 2012; 47:966–972.
8. Stephenson AL, Tom M, Berthiaume Y, et al. A contemporary survival analysis of individuals with cystic fibrosis: a cohort study. Eur Respir J. 2015; 45:670–679.
9. Hamosh A, FitzSimmons SC, Macek M, Jr., et al. Comparison of the clinical manifestations of cystic fibrosis in black and white patients. J Pediatr. 1998; 132:255–259.
10. O'Connor GT, Quinton HB, Kahn R, et al. Northern New England Cystic Fibrosis C. Case-mix adjustment for evaluation of mortality in cystic fibrosis. Pediatr Pulmonol. 2002; 33:99–105.
11. California Department of Public Health, Newborn Screening Program. Newborn Screening News 2017;15(Summer):1–4. http://www.cdph.ca.gov/programs/nbs/Documents/NBS-NBSNewsSummer07.pdf Accessed November 07, 2016.
12. Watts KD, Seshadri R, Sullivan C, McColley SA. Increased prevalence of risk factors for morbidity and mortality in the US Hispanic CF population. Pediatr Pulmonol. 2009; 44:594–601.
13. Kern AS, Watts KD, Rychlik K, McColley SA. Disparities in parental health literacy at a pediatric cystic fibrosis center. Pediatr Allergy Immunol Pulmonol. 2014; 28:55–59.
14. McGarry ME, McColley SA. Minorities are underrepresented in clinical trials of pharmaceutical agents for cystic fibrosis. Ann Am Thorac Soc. 2016; 13:1721–1725.
15. O'Connor GT, Quinton HB, Kneeland T, et al. Median household income and mortality rate in cystic fibrosis. Pediatrics 2003; 111:e333–e339.
16. Schechter MS, Shelton BJ, Margolis PA, Fitzsimmons SC. The association of socioeconomic status with outcomes in cystic fibrosis patients in the United States. Am J Respir Crit Care Med. 2001; 163:1331–1337.
17. Schechter MS, McColley SA, Regelmann W, et al. Investigators, Coordinators of the Epidemiologic Study of Cystic F. Socioeconomic status and the likelihood of antibiotic treatment for signs and symptoms of pulmonary exacerbation in children with cystic fibrosis. J Pediatr. 2011; 159:819–824 e811.
18. Schechter MS, McColley SA, Silva S, Haselkorn T, Konstan MW, Wagener JS. Investigators, Coordinators of the Epidemiologic Study of Cystic F, North American Scientific Advisory Group for E. Association of socioeconomic status with the use of chronic therapies and healthcare utilization in children with cystic fibrosis. J Pediatr. 2009; 155:634–639 e631–634.
19. American academy of pediatrics, council on community pediatrics, committee on nutrition. promoting food security for all children. Pediatrics 2015; 136:e1431–e1438.
20. American academy of pediatrics, section on tobacco control. clinical practice policy to protect children from tobacco, nicotine, and tobacco smoke. Pediatrics 2015; 136:1–10.
21. Konstan MW, Morgan WJ, Butler SM, et al. Scientific Advisory G, the I, Coordinators of the Epidemiologic Study of Cystic F. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr. 2007; 151:134–139 139 e131.
22. Sanders DB, Emerson J, Ren CL, et al. Early childhood risk factors for decreased FEV1 at age six to seven years in young children with cystic fibrosis. Ann Am Thorac Soc. 2015; 12:1170–1176.
23. Sanders DB, Fink A, Mayer-Hamblett N, et al. Early life growth trajectories in cystic fibrosis are associated with pulmonary function at age 6 years. J Pediatr. 2015; 167:1081–1088 e1081.
24. Saline Hypertonic in Preschoolers (SHIP). NCT02378467. https://clinicaltrials.gov/ct2/show/NCT02378467 Accessed November 7, 2016.
25. A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have a CFTR Gating Mutation. NCT02725567. https://clinicaltrials.gov/ct2/show/NCT02725567 Accessed November 7, 2016.